Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.555 | High risk elderly trauma related to fall in Hong Kong – a multicenter study |
Dr. YEUNG Hiu Hung 楊曉紅 |
| 2010.168 | Improving Trauma Care in Hong Kong through a Trauma Care System | Ms Yeung Hiu Hung |
| 2008.471 | Does gender affect mortaility and morbidity after acute traumatic brain injury? | Ms Yeung Hiu Hung |
| 2011.327 | Work-related injuries presenting to a regional trauma center - a ten year experience | Dr Yeung Hiu Hung |
| 2007.434 | Assessment of Health Status in Survivors of Severe Trauma in Hong Kong: Prospective Multi-Centre Cohort Study | Ms Yeung Hiu Hung |
| 2008.043 | Biycle-related Injuries Presenting to A Trauma Centre in Hong Kong | Ms Yeung Hiu Hung |
| 2019.537 | Counselling in Community Psychiatric Service - Clinical Practicum for The University of Hong Kong Master of Social Science (Counselling) | Ms. YEUNG Hei Wun |
| 2021.412 | Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor |
Dr. YEUNG David 楊駿文 |
| 2022.462 | Biological Typing of Sinonasal Diseases |
Dr. YEUNG David 楊駿文 |
| 2024.099 | A Randomised Controlled Trial of Ultrasound Guided Radiofrequency Ablation of Parotid Warthin's Tumor versus Parotidectomy |
Dr. YEUNG David David Chun Man |
| 2022.427 | Surgical Outcomes of U-shaped incision versus conventional incisions in parotidectomy | Dr. YEUNG David |
| 2023.094 | Randomized Controlled Trial of Bioabsorbable Steroid Eluting Stent in Frontal Sinus Opening for Endotype II Bilateral Chronic Rhinosinusitis with Nasal Polyps in the Asian Population | Dr. YEUNG David |
| 2025.060 | Olfactory Training for Smell Dysfunction Patients |
Dr. YEUNG David Dave Yeung |
| 2008.147 | Validity and Reliability of Skinfold Thickness Measurement in Assessing Body Density and Body Fatness in Chinese Children in Hong Kong Aged 6-19 Years Using Air Displacement Plethysmography as a Criterion Measure | Mr Yeung Daniel Chi Shing |
| 2016.183 | Impact of a Home-based Pharmaceutical Care Service on Medication Adherence and Quality of Life : A prospective observational study |
Ms. YEUNG Ching Ying 楊靜瀅 |
| 2017.620 | The effect of posture brace on balance in patients with osteoporotic vertebral fracture |
Miss YEUNG Ching Wing 楊靜穎 |
| 2009.279 | How does spinal stenosis affects the health-related quality of life of Chinese older people? | Miss Yeung Chi Yan |
| 2019.438 | Effects of An Advance Care Planning Programme for Persons With Early Dementia or Mild Cognitive Impairment And Their Family Caregivers in the Community: A Randomized Controlled Trial |
Ms. YEUNG Chi Yan 楊智恩 |
| 2005.160 | The Effect of Therapeutics Ultrasound in Healing Reptured Achilles Tendon in Human | YEUNG Chi Keung |
| 2018.008 | Genome-based resolution of gut microbiomes and viromes in patients with metabolic syndrome | Dr. YEOH Yun Kit |
| 2017.514 | Gut microbiome of individuals with metabolic syndrome | Dr. YEOH Yun Kit |
| 2020.015 | Effects of commercial antimicrobial mouthwash on oral microbial community composition | Dr. YEOH Yun Kit |
| 2020.354 | Tender for the Provision of Services of the Monitoring and Evaluation Study of Kwai Tsing District Health Centre and Sham Shui Po District Health Centre |
Prof. YEOH Eng Kiong 楊永強 |
| 2021.696 | Health Support Pilot Programme for South Asian Ethnic Groups |
Prof. YEOH Eng Kiong 楊永強 |
| 2015.359 | Quality of healthcare for the Ageing – Health system and service models to better cater for an ageing population | Prof. YEOH Eng Kiong |
| 2014.551 | Improving elderly healthcare voucher scheme to incentivise primary care in Hong Kong: How has health service utilization changed | Prof. YEOH Eng Kiong |
| 2017.193 | Modelling the Impact of Control Strategies for Tuberculosis Transmission in Hong Kong | Prof. YEOH Eng Kiong |
| 2023.102 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 | Prof. YEO Winnie Ming Ming |
| 2022.282 | A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study |
Prof. YEO Winnie 楊明明教授 |
| 2024.096 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Prof. YEO Winnie |
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2023.629 | A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) | Prof. YEO Winnie |
| 2023.269 | A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in a wide patient population with HR+ HER2-early breast cancer (Adjuvant WIDER) | Prof. YEO Winnie |
| 2023.267 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Prof. YEO Winnie |
| 2022.286 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
Prof. YEO Winnie 楊明明教授 |
| 2022.285 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) |
Prof. YEO Winnie 楊明明 |
| 2021.219 | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) |
Prof. YEO Winnie 楊明明教授 |
| 2021.162 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy |
Prof. YEO Winnie 楊明明教授 |
| 2022.510 | A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients with HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study) |
Prof. YEO Winnie 楊明明 |
| 2022.173 | EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation |
Prof. YEO Winnie 楊明明教授 |
| 2024.137 | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) | Prof. YEO Winnie |
| 2020.653 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
Prof. YEO Winnie 楊明明教授 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2020.330 | Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients |
Prof. YEO Winnie 楊明明教授 |
| 2018.392 | A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) |
Prof. YEO Winnie 楊明明 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2019.551 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2018.435 | A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) |
Prof. YEO Winnie 楊明明 |
| 2018.363 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
Page 13 of 262.